tbuckley/cabot-search huggingface dataset:
Osteosarcoma of the pelvis and sacrum: A retrospective analysis of 73 patients.
Authors: E. Palmerini, N. Fabbri, E. L. Staals, E. Marchesi, M. Alberghini, A. Tienghi, F. Fagioli, P. Picci, M. Mercuri, S. Ferrari
Journal: Journal of Clinical Oncology (2011)

10039 Background: Treatment of pelvic and sacrum osteosarcoma (OS) poses challenges for local control and outcome. Data are scarce since these patients (pts) are often not eligible for chemotherapy protocols. Methods: All pts with high grade pelvic or sacral OS admitted to the Rizzoli Institute between 1998 and 2010 were included in this retrospective study. Results: 73 pts (40 male) were identified; median age was 32 years (8-72); 60 (82%) had pelvic and 13 (18%) sacral lesions. Fifty-five (75%) pts presented with localized disease. Forty-eight (66%) underwent surgery (and hindquarter amputation in 37% of cases, with adequate surgical margins in 78%). A surgical complete remission (SCR) was achieved in 56% of pts. Chemotherapy: 3 Drugs [cisplatin, adriamycin and standard dose ifosfamide (IFO)] were administered to 16 pts; 4 Drugs (cisplatin, adriamycin, IFO and methothrexate) to 19 pts; 4 Drugs with high dose ifosfamide (HDIFO: 15 gr/m2) in 21. Four pts did not receive chemotherapy; 13 pts received other systemic agents. A good histological response to neo-adjuvant chemotherapy was reported in 6 out of 37 pts (16%). With a median follow-up of 21 months (1-134), the 5-year overall survival (OS) was 22% (95%CI 11-33): 28% for localized and 0 for metastatic pts (p=0.002); 40% in pts with surgical complete remission (SCR) and 3% for no SCR (p=0.001). The 5-year disease-free survival (DFS) was 29% (95%CI 13-46). In localized pts a trend towards a better 5-year-OS was shown for more intensive treatment [3 Dugs 21% (95%CI 0-56), 4 Drugs 31% (95%CI 8-55), 4 Drugs plus HDIFO 38% (95%CI 10-65), other regimens 20% (95%CI 0-55), no chemotherapy 0%], younger age [pediatric 42% (95%CI 0-85), adults 32% (95%CI 13-51), >40-years 23% (95%CI 10-46)], pelvic site [pelvis 32% (95%CI 16-48), sacrum 11% (95%CI 0-32)], and adequate surgical margins [adequate 41% (95%CI 20-61), inadequate 23% (95%CI 16-61)]. Conclusions: Metastatic OS of the pelvis and sacrum is invariably fatal. Surgery is pivotal for survival. In spite of an aggressive systemic treatment, the prognosis is poor even for pts in SCR. The lower rate of good histological responses for these lesions, compared with extremity tumors, suggests a different biological behavior. New treatment strategies are warranted.
Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.
Authors: T. E. Hutson, S. Bracarda, B. Escudier, C. Porta, R. A. Figlin, E. Calvo, V. Grunwald, A. Ravaud, E. Kpamegan, R. J. Motzer
Journal: Journal of Clinical Oncology (2011)

312 Background: In the RECORD-1 phase III study, the mammalian target of rapamycin (mTOR) inhibitor everolimus (ClinicalTrials.gov: NCT00410124 ) prolonged progression-free survival (PFS) versus placebo (median PFS 4.9 vs 1.9 months) in patients with mRCC whose disease progressed during or within 6 months of VEGFr-TKI (sunitinib and/or sorafenib) therapy. In this retrospective analysis, we evaluated the effect of everolimus on PFS in the subgroup of patients who discontinued prior VEGFr-TKI therapy because of adverse events. Methods: In the randomized, double-blind RECORD-1 trial, patients with mRCC who had prior VEGFr-TKI therapy were randomized (2:1) to receive everolimus 10 mg/day (n = 277) or placebo (n = 139) plus best supportive care. Results: Patients who were intolerant of prior VEGFr-TKI therapy included 50 patients (sunitinib = 26; sorafenib = 24) in the everolimus group and 13 patients (sunitinib = 5; sorafenib = 8) in the placebo group. The median PFS in the sunitinib group was 5.13 mo (95% confidence interval [CI]: 3.71, not available [NA]) in patients receiving everolimus vs 2.81 mo (95% CI: 1.87, 3.71) in those receiving placebo (HR: 0.28; 95% CI: 0.07, 1.18; p = 0.033). In the sorafenib subgroup, median PFS was 5.59 mo (95% CI: 3.78, NA) versus 1.91 mo (95% CI: 1.68, 3.48), respectively (HR: 0.29; 95% CI: 0.09, 0.91; p = 0.012). Conclusions: Everolimus prolonged PFS in a subgroup of patients with mRCC who were intolerant of prior VEGFr-TKI therapy. These results suggest that mTOR inhibition with everolimus was active in patients with mRCC who were intolerant of a previous VEGFr-TKI. [Table: see text]
The PTPN22 1858C/T Polymorphism Is Associated with the Development of Grade 3 to 4 Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation Following Nonmyeloablative Conditioning.
Authors: Brian Kornblit, Tania Masmas, Soren L. Petersen, Hans O. Madsen, Peter Garred, Lars Vindelov
Journal: Blood (2007)
Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia
Authors: Maria Luisa Sulis, Traci M. Blonquist, Uma H. Athale, Luis A. Clavell, Peter D. Cole, Kara M. Kelly, Caroline Laverdiere, Jean-Marie Leclerc, Bruno Michon, Marshall A. Schorin, Jennifer J.G. Welch, Donna S Neuberg, Stephen E. Sallan, Lewis B. Silverman
Journal: Blood (2015)
BILE ACID-PRECONDITIONING PROTECTS HEPATOCYTES AGAINST BILE ACID-INDUCED APOPTOSIS IN AN IN VITRO MODEL OF CHOLESTATIC LIVER DISEASE
Authors: Esther M. Verhaag, Golnar Karimian, Manon Buist-Homan, Klaas Nico Faber, Han Moshage
Journal: Hepatology (2011)
Injury of Peribiliary Glands of Donor Liver Bile Ducts Plays a Pivotal Role in the Development of Non-anastomotic Biliary Strictures after Liver Transplantation
Authors: Negin Karimian, Sanna op den Dries, Pepijn D. Weeder, Andrie Westerkamp, Fernanda Bomfati, Jantje Wiersema-Buist, Bote G. Bruinsma, Annette S. Gouw, James F. Markmann, Ton Lisman, Heidi Yeh, Korkut Uygun, Paulo N. Martins, Robert J. Porte
Journal: Hepatology (2014)
Clinicopathologic features and prognosis of triple-negative breast cancer: 10-years experience from Kuwait.
Authors: M. El-Sherify, M. S. Fayaz, S. Abuzalouf, A. AL Basmy, N. Nazmy
Journal: Journal of Clinical Oncology (2011)

e11500 Background: Triple negative breast cancer (TNBC) is defined as a subtype that is negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). There is a growing evidence of the heterogeneity of such entity on the molecular level that may cause discrete outcomes. The aim of this study is to determine the incidence of TNBC in Kuwait, to analyze the clinicopathologic features and prognosis of this type of breast cancer, and define favorable prognostic factors. Methods: We analyzed the clinicopathologic features of 363 TNBC cases which were diagnosed in Kuwait from July 1999 to June 2009. The disease-free survival (DFS) and overall survival (OS) were analyzed by Kaplan-Meier method. Results: Among 2,986 patients diagnosed with breast cancer in Kuwait, 363 patients (12.2%) were TNBC. The median age at diagnosis was 48 years in which 24.2% were under 40 years. 57.2% had lymph nodes (LN) metastasis, 56.9% of grade III tumor and 21.5% of family history of breast cancer. 41.9% had stage II disease while 37.1% had stage III and 7.1% had IV. Lymphovascular invasion (LVI) was documented in 58.6% of patients. Menopausal status, tumor size, pathological subtype, nodal metastasis, type of surgery, number of dissected LN and LVI were correlated with the DFS and OS. 81% of recurrences and 75% of deaths occurred by 2.5 years after treatment. Conclusions: The incidence of TNBC in our study is similar to other published studies. TNBC patients showed an early major recurrence surge peaking at approximately year 2.5. Only the tumor stage showed independent prognostic effect on TNBC outcomes. Patients with small tumors, no LN metastasis and favorable histopathology had comparable outcomes to non-TNBC.
Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation
Authors: Christine Wolschke, Stefan O Schonland, Ute Hegenbart, Thomas Stübig, Marion Heinzelmann, York Hildebrandt, Michael Lioznov, Axel R. Zander, Nicolaus Kröger
Journal: Blood (2010)
Phase I/II Study of the Rituximab-EPOCT Regimen in Combination with G-CSF in Patients with Relapsed or Refractory Follicular Lymphoma Including Evaluation of Its Cardiotoxicity Using B-Type Natriuretic Peptide and Troponin T Levels.
Authors: Nozomi Niitsu, Mika Khori, Miyuki Hayama, Masaaki Higashihara, Jun-ichi Tamaru
Journal: Blood (2004)
Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients
Authors: Razelle Kurzrock, David J. Stewart
Journal: Clinical Cancer Research (2016)

Abstract Following the approval of bevacizumab, an antibody targeting VEGF-A, for advanced non-squamous non–small cell lung cancer (NSCLC) in 2006, intensive efforts were put into the clinical development of antiangiogenic agents for NSCLC. Currently, the other antiangiogenic agents approved for NSCLC are ramucirumab, a VEGF receptor-2 (VEGFR-2)–targeting antibody indicated for both squamous and non-squamous NSCLC in the United States, and nintedanib, an anti–VEGFR-1/2/3, platelet-derived growth factor receptor-α/β, fibroblast growth factor receptor-1/2/3 angiokinase inhibitor indicated for adenocarcinoma of the lung in the European Union. Many other antiangiogenic agents are being evaluated in phase III trials for NSCLC, including aflibercept, sunitinib, sorafenib, cediranib, and vandetanib. Although many of the same signaling pathways are targeted by these novel agents, mixed efficacy results have been observed in these trials. Moreover, safety issues have raised concerns about using antiangiogenic agents in this patient population, and fatal bleeding events have been reported. Importantly, although no biomarker has yet been validated for antiangiogenic agents in NSCLC, biomarkers that show potential include circulating levels of short VEGF-A isoforms, expression of neuropilin-1 and VEGFR-1 in tumors and plasma, genetic variants in VEGF-A and VEGFR, and tumor protein p53 mutations (with the latter having been shown to correlate with increased levels of VEGF-A transcripts). This review provides an overview of the clinical benefit and risk associated with the use of antiangiogenic agents for NSCLC, and summarizes the research to date on the identification of predictive biomarkers for antiangiogenic therapies. Clin Cancer Res; 23(5); 1137–48. ©2016 AACR.
Adjuvant therapy in resected pancreatic cancer: A systematic review of literature with meta-analysis of randomized clinical trials.
Authors: Fabrizio Drudi, Davide Tassinari, Claudio Ridolfi, Alessandra Affatato, Emiliano Tamburini, Carlotta Santelmo, Federica Carloni, Lorenzo Gianni, Luigi Veneroni, Gabriele Donati, Alberto Ravaioli
Journal: Journal of Clinical Oncology (2012)

342 Background: To assess the role of adjuvant treatments (AT), adjuvant chemotherapy (AC) and adjuvant chemo-radiotherapy (ACR) in resected pancreatic adenocarcinoma. Methods: A systematic review of literature in the MEDLINE and EMBASE data bases from 1966 to 2011 was independently performed by two authors (FD and DT). All the randomized phase III trials investigating the role of AT in radically resected pancreatic cancer were considered eligible and included into the pooled analysis. 5-year-survival rate in patients treated with AT was the primary end point of the trial, 5-year-survival rate of patients treated with AC and ACR, and the 5-year-survival number needed to treat (NNT) of AT, AC and ACR were the secondary ones. Results: The outcomes of 1402 patients enrolled in 8 trials were compared in the pooled analysis. 816 patients were treated with AT (540 with AC and 276 with ACR), and 586 were enrolled in the control arm (no adjuvant treatment). Significant improve in 5-year-survival rate was observed for AT and AC (odds ratio of 0.636, p&lt;0.05 and 0.422, p&lt;0.01 respectively), but not for ACR (odds ratio=1.139, p=0.489), with a 5-year survival NNT of 20, 10 and 38 respectively for AT, AC and ACR. Low to moderate heterogeneity between the trials was documented both for AT (I 2 =58%) and AC (I 2 =31.63%), but not for ACR (I 2 =0%,). Conclusions: Our data confirm that adjuvant chemotherapy improves the 5-year survival rate in radically resected cancer patients and gemctabine based regimens seem to be better than FU based regimens.
Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.
Authors: Martino Introna, Gianmaria Borleri, Elena Conti, Anna M. Barbui, Raewyn Broady, Erica Dander, Giuseppe Gaipa, Giovanna D’Amico, Ettore Biagi, Matteo Parma, Enrico Pogliani, Orietta Spinelli, Donatella Baronciani, Anna Grassi, Josee Golay, Tiziano Barbui, Andrea Biondi, Alessandro Rambaldi
Journal: Blood (2006)
Morphology of Bone Marrow Plasma Cells (BMPC) and Its Relationship with Interphase Cytogenetics and Prognosis in Multiple Myeloma (MM).
Authors: Xavier Leleu, Jean E. Goasguen, Claire Mathiot, Richard Garand, Murielle Roussel, Michel Attal, Philippe Moreau, Jean-Luc Harousseau, Thierry Facon, Hervé Avet-Loiseau, Marc Zandecki
Journal: Blood (2009)
Assessment of shoulder pain for non-specialists
Authors: Matthew Gray, Alasdair Wallace, Stephen Aldridge
Journal: BMJ (2016)

#### What you need to know



 

With more than 120 different “special tests” of the shoulder described,1 it is easy to see how its assessment can seem an enigma for non-specialists. Shoulder pain is common, and most cases will be managed in the community.2 Its prevalence in Dutch primary care is around 11 per 1000 patients seen each year,3 and as many as two in three people may experience it at some point in their life.4

Most diagnoses can be made from the patient’s history and examination considering relevant risk factors such as age, occupation, previous trauma, and relevant comorbidities. Here, we simplify the process of shoulder assessment to empower non-specialists evaluating a patient presenting with shoulder pain for the first time and provide an update on common shoulder pathologies.

Take a targeted history —For some guide questions, see box 1. Watch out for features that may warrant secondary care specialist referral, orthopaedic or otherwise (fig 1⇓).5

#### Box 1: Questions for a targeted shoulder pain history



Fig 1 Red flags for shoulder pain that warrant urgent referral. Images adapted from BMJ Best Practice (http://bestpractice.bmj.com/best-practice/monograph/709.html), Physiopedia (www.physio-pedia.com/Shoulder_Dislocation), LITFL (http://lifeinthefastlane.com/a-funny-fracture/ …
Evaluation of Progenitor Cells (CFU-GM, CFU-GEMM, BFU-E, CD34+ Cells) and White Blood Cells in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with Rituximab-CHOP-14 and Supported with Pegfilgrastim.
Authors: Maurizio Bonfichi, Ercole Brusamolino, Carmela Marseglia, Chiara Rusconi, Mario Lazzarino
Journal: Blood (2005)
An “ecological” action-based synthesis
Authors: Jonathan de Vries, Lawrence M. Ward
Journal: Behavioral and Brain Sciences (2016)

We expand upon Morsella et al.'s synthesis in the direction of what Gibson (1979) called an ecological approach to perception. Morsella et al. describe consciousness as a director of voluntary action, but they understate the role of the environment in its evolution as well as in directing behavior. We elaborate these roles in the context of the concept of affordances.
Augmentation of Vasculogenesis by Injected Human Hematopoietic Stem Cells in Response to Ischemia Follows Early Activation of Innate Immune Response.
Authors: Marcie R. Finney, Laura R. Fanning, Margaret Kozik, Shigemi Matsuyama, Matthew E. Joseph, Johnathan L. Goldberg, Nicholas J. Greco, Peter Haviernik, Pingfu Fu, Vincent J. Pompili, Mary J. Laughlin
Journal: Blood (2007)
Is obesity associated with increased recurrence risk in estrogen receptor (ER)-positive breast cancer?
Authors: K. K. L. Yap, D. N. Efiom-Ekaha
Journal: Journal of Clinical Oncology (2011)

171 Background: Oncotype DX Score is a 21-gene expression analysis that has been validated clinically as a reliable predictor of breast cancer recurrence for ER-positive, node-negative breast cancers. Obesity is recognized as a risk factor for many cancers, including breast cancer. Additionally obesity has been shown to be an independent prognostic factor in breast cancer. The primary objective of this study is to determine the correlation between obesity and Oncotype DX score, hence the relationship between obesity and breast cancer recurrence in ER-positive breast cancer. The secondary objective is to investigate the association between weight gain after diagnosis and breast cancer recurrence. Methods: An IRB-exempted retrospective chart review of female patients at Wellspan Group with ER-positive breast cancer who had Oncotype DX analysis in 2008 and 2009. Data collected included Oncotype DX score and BMI (at diagnosis, 6 months and 12 months). Data were analyzed to determine the correlation between Oncotype DX score and BMI at diagnosis, at 6 months and at 12 months. The correlation between Oncotype DX score and BMI changes at 12 months also was determined. Results: A total of 125 patients were identified; 103 had BMI recorded at diagnosis, 88 had BMI recorded at 6 months and 87 had BMI recorded at 12 months. Of these, we were able to determine the BMI changes at 12 months for 82 patients. The Pearson correlation scores were 0.091 (p = 0.361), 0.074 (p = 0.492), and 0.047 (p = 0.669) for BMI at diagnosis, at 6 months and at 12 months respectively. The Pearson correlation score was 0.007 (p = 0.948) for BMI changes at 12 months. Conclusions: Obesity and weight gain are not independent predictors of recurrence in patients with ER-positive breast cancer. The reported adverse prognostic associations may be more prominent in ER-negative breast cancers. This is consistent with the reports suggesting a higher rate of ER-negative, high-grade cancers in obese women as well as a greater magnitude of benefit from dietary and weight reduction interventions seen in women with ER-negative cancers.
Cisplatin resistance is associated with reduced lysosomal structures and markers in ovarian cancer cells.
Authors: Roohangiz Safaei, Kuniyuki Katano, Goli Samimi, Alison K. Holzer, Wiltrud Naerdemann, Stephen B. Howell
Journal: Cancer Research (2004)

3747  Lysosomes are acidic organelles with numerous functions in protein turnover, surface receptor regulation, release of endocytosed nutrients, and plasma membrane repair. Lysosomal involvement in mediating resistance to anticancer drugs, including cisplatin (DDP), has been suggested previously. We compared 3 pairs of isogenic DDP-sensitive and resistant ovarian carcinoma cell lines (2008 and 2008/C13*5.25, A2780 and A2780/CP, and IGROV-1 and IGROV-1/CP) for the size of the lysosomal compartment and the expression of the lysosome-associated proteins 1 and 2 (LAMP1 and LAMP2) using confocal microscopy and Western blotting. Effects of lysomotrophic drugs bafilomycin A1 and chloroquine on the subcellular distribution of a fluorescein-labeled DDP (F-DDP) were also examined in 2008 and 2008/C13*5.25 cells, using the vital dye Lysotracker Red and antibodies to LAMP1 and LAMP2. The size of the lysosomal compartment was significantly reduced in all 3 DDP-resistant cell lines as evidenced by a marked decrease in the number of structures labeled by Lysotracker Red or anti-LAMP and anti-LAMP2 antibodies on microscopy. Analysis of images with Near Count software indicated that the number of pixels that corresponded to lysosomal structures in 2008/C13*5.25 resistant line was only 40% of that in the sensitive 2008 cells (p
Cardiomyopathy in Muscular Dystrophy
Authors: Elizabeth M. McNally
Journal: JAMA Cardiology (2016)

Marly Conceição Silva, MD, PhD; Tiago Augusto Magalhães, MD, PhD; Zilda Maria Alves Meira, MD, PhD; Carlos Henrique Reis Esselin Rassi, MD; Amanda Cristina de Souza Andrade, MS; Paulo Sampaio Gutierrez, MD, PhD; Clerio Francisco Azevedo, MD, PhD; Juliana Gurgel-Giannetti, MD, PhD; Mariz Vainzof, MD, PhD; Mayana Zatz, PhD; Roberto Kalil-Filho, MD, PhD; Carlos Eduardo Rochitte, MD, PhD
Radioulnar Synostosis-Hematology (RUS-H) Syndrome: Description of the New Syndrome and Comparison to Similar Syndromes
Authors: Evangelista E Jessie, Mary M. Ruisi, Daniel Green, Rachel Burt, Jaclyn Davis, Regina A. Macatangay, Farid Boulad, Shivani Shah, Brenda Oiyemhonlan, Benjamin T. Kile, James B Bussel
Journal: Blood (2012)
The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer.
Authors: U. Ortmann, J. Salmen, P. G. M. Hepp, M. W. Beckmann, T. N. Fehm, H. Hindenburg, W. Lichtenegger, B. K. Rack, A. Schneeweiss, W. Janni
Journal: Journal of Clinical Oncology (2011)

1070 Background: Taxane-based anthracycline containing chemotherapy has been established as treatment option in the adjuvant setting of early breast cancer. Indication was recently enlarged for high risk node negative breast cancer. Promising retrospective data indicate equi-efficacy of anthracycline-free chemotherapy in Her2/neu-negative patients (Gennari et al., Slamon et al.). Anthracycline-free regimens are probably associated with less long-term toxicities, especially cardiac toxicities. Methods: The SUCCESS-C trial is an open-label, multicenter, 2x2 factorial design, randomized controlled, phase III study comparing the disease free survival in patients treated with 3 cycles fluorouracil 500mg/m2-epirubicine 100mg/m2-cyclophosphamide 500mg/m2 (FEC) chemotherapy, followed by 3 cycles docetaxel 100mg/m2 (D) chemotherapy, versus 6 cycles docetaxel 75mg/m2-cyclophosphamide 600mg/m2 (DC) chemotherapy. Monitored toxicity data after end of treatment are available from 1,452 patients. Results: Chemotherapy was prematurely stopped in 51 pts (7.2%) receiving FEC-D and in 57 pts (7.7%) with DC (p=0.71). Dose reductions occurred significantly more often in the FEC-D arm (2.7%) than in the DC arm (1.9%, p=0.024), reasons did not differ significantly between both arms (p=0.093). Incidence of treatment-postponement was significantly higher for FEC-D (9.4% FEC-D vs. 7.6% DC; p=0.0008). Haematological toxicity as a reason for treatment-postponement occurred significantly more frequent within the FEC-D-arm (FEC-D: 18.1%, DC: 6.6%, p<0,0001); non-haematological toxicity as a reason for treatment postponement was nearly equal within both arms (8.6% FEC-D vs. 8.8% DC, p=0.9). G-CSF support was applied in 22.7% of all chemotherapy cycles (FEC-D: 22.2% vs. DC: 23.2%, p=0.21). Severe toxicities (NCI-grade > 2) were reported in 910 cases for FEC-D and in 848 cases for DC arm (p= 0.02). Conclusions: Significantly more dose-reductions of chemotherapy and a significant higher incidence of treatment-postponement occurred in the FEC-D arm. The toxicity profiles of both treatment arms differ discretely and support the continuation of the trial until target recruitment (n=3,547).